Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Long-term data on R-CHOP in follicular lymphoma

Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31

Key clinical point: Long-term data shows that R-CHOP is effective and safe as first-line treatment of patients with follicular lymphoma.

Major finding: Approximately one-third of patients treated with R-CHOP-14 plus G-CSF or R-CHOP-21 had no disease progression after 10 years of follow-up.

Study details: Long-term analysis of a randomized phase 2/3 trial in 299 patients with indolent B-cell lymphomas, including follicular lymphoma.

Disclosures: The study was supported by the Ministry of Health, Labor and Welfare of Japan and by the National Cancer Center Research and Development Fund of Japan. Dr. Wantanabe has received honoraria from Bristol-Myers Squibb, Takeda, Taisho Toyama, Celgene, Nippon Shinyaku, and Novartis and funding resources from TakaraBio and United Immunity to support the Department of Immuno-Gene Therapy in Mie University. Multiple coauthors reported similar relationships.

Read the article here.


Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44.

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Must Reads in B Cell Lymphoma

Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31

5F9 plus rituximab looks durable in NH, Advani R et al. N Engl J Med. 2018;379:1711-21

Bortezomib plus VR-CAP looks promising in untreated MCL, Robak T et al. Lancet Oncol. 2018 Oct 19. doi: 10.1016/S1470-2045(18)30685-5

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Phase 2 trial evaluates entospletinib in DLBCL, Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331